Adipokines belong to a group of proteins involved in the pathogenesis and progression of immune/inflammatory diseases. It is an open question whether and how adipokines contribute to these diseases. Adiponectin might be a key regulator of the immune system, playing a role in the progression of inflammatory disorders. Omentin has been recognized as an anti-inflammatory adipokine with influence on immune response regulation and inflammation, Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by vasculopathy and fibrosis of the skin and internal organs. The studies showed a possible role of adipokines in the development of fibrosis and modulation of the immune response in the course of SSc. We aimed to evaluate plasma levels of adiponectin and omentin-1 in SSc patients in basal conditions as well as in prospective observations.
Material and Methods: 59 patients with SSc and 27 healthy controls, matched with age, BMI and HOMA-IR, were enrolled in the study. The severity of the skin fibrosis in SSc individuals was evaluated using the Rodnan scale. In all participants, fasting plasma adiponectin and omentin-1 concentrations were assessed using the ELISA.
Results: Omentin-1 levels were significantly higher in patients with SSc compared with the controls. These differences remained marked after adjustment to BMI. No changes were seen between omentin-1 concentrations in prospective analyses in SSc patients (0, 6 months, 9 months). Although adiponectin had a trend to lower values in SSc individuals in comparison to the controls, the differences were not significant. However, after adjustment to BMI, these differences became significant. Similar to omentin-1, there were no adiponectin fluctuations in the follow-up. Amongst two selected adipokines, only adiponectin levels correlated with the Rodnan scale (R = −0.21, P < 0.05). To conclude, adiponectin and omentin-1 cannot be regarded as potential metabolic markers of a course of systemic sclerosis. However, higher omentin-1 and lower adiponectin concentrations after adjustment to BMI, as seen in SSc patients, may indicate an influence of these adipokines on pathomechanisms involved in systemic sclerosis.
|SSc||Control||P||P (after adjustment to BMI)|
|Adiponectin (ug/ml)||8.47 ± 4.06||10.6 ± 5.4||ns||< 0.05|
|Omentin-1 (ng/ml)||604 ± 93||506 ± 138||< 0.05||< 0.05|
|0||6 months||9 months||p|
|Adiponectin (mg/ml)||8.47 ± 4.06||8.72 ± 3.85||8.04 ± 3.81||ns|
|Omentin-1 (ng/ml)||604 ± 193||619 ± 257||601 ± 238||ns|
This study was supported by the CMKP grant 506-1-31-22-19.
05 Sep 2020 - 09 Sep 2020